MARKET

ARVN

ARVN

Arvinas
NASDAQ
7.15
-0.27
-3.64%
Closed 17:17 06/08 EDT
OPEN
7.49
PREV CLOSE
7.42
HIGH
7.55
LOW
7.13
VOLUME
692.61K
TURNOVER
--
52 WEEK HIGH
14.51
52 WEEK LOW
6.06
MARKET CAP
461.33M
P/E (TTM)
-2.1957
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ARVN last week (0601-0605)?
Weekly Report · 1d ago
Arvinas joins MJFF-backed PPMI study to support development of LRRK2 degrader ARV-102 for Parkinson’s
PUBT · 5d ago
ARVINAS JOINS THE MICHAEL J. FOX FOUNDATION’S LITE AND PPMI PROGRAMS TO ADVANCE NEW THERAPIES TARGETING LRRK2 FOR PARKINSON’S DISEASE
Reuters · 5d ago
Arvinas Price Target Maintained With a $18.00/Share by Stephens & Co.
Dow Jones · 6d ago
Stephens & Co. Reiterates Overweight on Arvinas, Maintains $18 Price Target
Benzinga · 6d ago
Analysts Conflicted on These Healthcare Names: Arvinas Holding Company (ARVN), Lyell Immunopharma (LYEL) and Relay Therapeutics (RLAY)
TipRanks · 6d ago
Arvinas Holding Company (ARVN) Gets a Buy from Barclays
TipRanks · 6d ago
Arvinas Reprioritizes Pipeline, Out-Licenses ARV-806 Development
TipRanks · 6d ago
More
About ARVN
Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393, ARV-102, ARV-80, and ARV-027. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC to degrade BCL6, a transcriptional repressor and a regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.

Webull offers Arvinas Inc stock information, including NASDAQ: ARVN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARVN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARVN stock methods without spending real money on the virtual paper trading platform.